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Abstract
Next-generation sequencing (NGS) is a valuable tool for the detection and quantification of HIV-1 variants in vivo. However,
these technologies require detailed characterization and control of artificially induced errors to be applicable for accurate
haplotype reconstruction. To investigate the occurrence of substitutions, insertions, and deletions at the individual steps of
RT-PCR and NGS, 454 pyrosequencing was performed on amplified and non-amplified HIV-1 genomes. Artificial
recombination was explored by mixing five different HIV-1 clonal strains (5-virus-mix) and applying different RT-PCR
conditions followed by 454 pyrosequencing. Error rates ranged from 0.04–0.66% and were similar in amplified and non-
amplified samples. Discrepancies were observed between forward and reverse reads, indicating that most errors were
introduced during the pyrosequencing step. Using the 5-virus-mix, non-optimized, standard RT-PCR conditions introduced
artificial recombinants in a fraction of at least 30% of the reads that subsequently led to an underestimation of true
haplotype frequencies. We minimized the fraction of recombinants down to 0.9–2.6% by optimized, artifact-reducing RT-
PCR conditions. This approach enabled correct haplotype reconstruction and frequency estimations consistent with
reference data obtained by single genome amplification. RT-PCR conditions are crucial for correct frequency estimation and
analysis of haplotypes in heterogeneous virus populations. We developed an RT-PCR procedure to generate NGS data useful
for reliable haplotype reconstruction and quantification.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) is a highly
diverse virus, not only on a global scale, but also within individual
HIV-1 infected subjects [1]. The genetic variants constituting the
viral population are called haplotypes, and these haplotypes form a
viral quasispecies [2]. It has been shown that low-abundant
haplotypes are already present in patients shortly after infection
[3–6]. Numerous studies have shown that minority drug-resistant
HIV-1 variants can be clinically relevant and lead to therapy
failure, especially in the context of pre-existing minority variants
harbouring resistance mutations to non-nucleoside reverse tran-
scriptase inhibitors (NNRTI) [7–10].
Viral diversity has major implications on pathogenesis, drug
resistance, and vaccine development. Since next-generation
sequencing (NGS) platforms are widely available, virus popula-
tions can be studied much faster compared to the classical
methodology of single genome sequencing. However, these
technologies require rigorous estimation of error rates and
identification of error sources, especially when viral haplotypes
are quantified (reviewed in [11]). For instance, several studies have
investigated the accuracy of the pyrosequencing technology, and it
is well known that homopolymeric regions are the main source of
insertion-deletion (indel) errors [12,13]. Moreover, the PCR
polymerase can also contribute to this effect [14]. PCR artifacts
are well known and addressed by optimizing PCR conditions and
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using high fidelity DNA polymerases [15]. Recently, primer
identifiers have been described to circumvent some of the
remaining PCR artifacts [16].
So far, not much attention has been drawn to the cDNA
synthesis that is required as first step when RNA, rather than
DNA, is the source for genetic analyses. RTs are error-prone
enzymes [17], and misincorporations during cDNA synthesis are
difficult to avoid and almost impossible to distinguish from real
variations, especially in heterogeneous viruses such as HIV-1.
In vitro recombination has almost exclusively been studied on
DNA templates and numerous improved PCR conditions have
been described [18–28]. Amplifying a heterogeneous DNA sample
can lead to artificial chimeras and therefore to an overestimation
of genetic variation [18,24,25]. PCR-mediated chimeras are
mainly created by prematurely terminated template extensions
during PCR and subsequent false priming of these short sequences
to a non-homologous sequence in the following cycles [21,23]. A
previous study has shown that PCR-induced recombinants can
account for up to 30% of the final PCR product [19]. Several
factors can influence PCR-induced in vitro recombination, includ-
ing template amount and polymerase processivity [20–22], but
in vitro recombination induced by reverse transcription is poorly
studied. So far, only Fang and co-workers studied HIV-1 cDNA
synthesis-induced in vitro recombination and showed that a 2.5-
fold higher in vitro recombination rate can be observed in RT-PCR
compared to DNA PCR when a long 4.5 kb fragment is amplified,
probably due to prematurely terminated cDNA synthesis or RNA
molecules degraded prior to the RT reaction [29].
Minimizing in vitro recombinants is particularly important when
studying the intra-patient diversity of viruses like HIV-1. Besides a
high mutation rate, this virus has the natural ability to recombine,
which is one of several options of HIV-1 to circumvent selection
pressures and to adapt to a new host [30,31].
Here, we estimated the error rates and characterized possible
error sources for the 454 pyrosequencing technology at all stages
of the procedure. We established an optimized, artifact-reducing
RT-PCR protocol to reverse transcribe, amplify, and pyrose-
quence HIV-1 RNA genomes enabling accurate haplotype
analysis based on entire sequence reads.
Results
Substitution and Insertion/Deletion Rates and their
Sources
To estimate the error rates of the different steps in the
procedure of 454 pyrosequencing, the protease gene of the virus
strain HIV-1JR-CSF was amplified and 454 pyrosequenced
following three different experimental procedures. In the first
procedure, the plasmid pYK-JRCSF, containing the full-length
sequence of HIV-1JR-CSF, was digested using restriction enzymes
flanking the protease gene. Adaptors were ligated to the protease
gene to obtain a fragment for direct 454 pyrosequencing. We refer
to this sample as ‘‘NGS’’ (figure 1A). It is used to evaluate the
substitution and indel (insertions and deletions) rates of the
emulsion PCR and the pyrosequencing procedure. In the second
set-up, the exact same plasmid preparation was used to amplify the
protease gene using fusion primers that consist of a HIV-1 specific
region, a multiplex identifier and either the A or B sequence
required for 454 pyrosequencing. This sample is named ‘‘PCR-
NGS’’, as only one, the inner, PCR was done to obtain the
amplicon (figure 1A). This experiment was performed to estimate
the substitution and indel rates of PCR, emulsion PCR, and
pyrosequencing. In the third set-up, again the same plasmid
preparation was used to produce the virus stock HIV-1JR-CSF from
which viral RNA was isolated and reverse transcribed followed by
outer and inner PCRs. This sample is named ‘‘RT-2PCR-NGS’’
(figure 1A). This set-up was used to estimate the substitution and
indel rates of the complete procedure that is commonly applied to
pyrosequence HIV-1 from patients’ plasma samples (RT, outer
PCR, inner PCR, emulsion PCR, and pyrosequencing).
All three experimental procedures were set up in duplicates and
pooled before pyrosequencing. Reads were aligned to the HIV-
1JR-CSF reference sequence, forward and reverse reads were
analyzed separately (see Materials and Methods). Every difference
between a read and the reference was counted as an error. Table 1
depicts the average substitution and indel rates per nucleotide for
each sample. The substitution rates per nucleotide varied between
0.08–0.16%, not showing clear patterns in regard to either the
different experimental procedures nor to forward and reverse
reads. In contrast, indel rates varied considerably. In comparison,
deletion rates were 2.7–5.5 -fold lower in reverse reads than in
forward reads obtained from PCR-NGS and RT-2PCR-NGS
samples and approximately twofold higher in reverse reads of
NGS samples (table 1). Insertion rates varied less in forward and
reverse reads of PCR-NGS and RT-2PCR-NGS samples, but they
were .3-fold higher in reverse reads than in forward reads of
NGS samples. The analysis of substitution and indel rates per
position in forward and reverse reads revealed that these errors
occurred mainly in the context of homopolymers (figure 1B). The
longest homopolymer (six guanines) is located at position 18–23
(figure 1B). It mainly caused artificial deletions in forward reads
and insertions in reverse reads, explaining the differences in
average error rates (table 1).
Characterization of Molecular HIV-1 Clones
293T cells were transfected separately with five different HIV-1
full-length plasmids to obtain molecular HIV-1 clones. As a
control, each of them was 454 pyrosequenced separately to
estimate the substitution and indel rates and to exclude the
presence of any recombinants in these virus stocks. Between
approximately 5,000 and 34,000 reads were analyzed per sample.
Within the 271 base pairs (bp) long analyzed region of the viral
protease gene, the mean substitution rates were on average 0.09%
per nucleotide and evenly distributed among the amplicons,
except the high substitution rates within the six-G homopolymer
region of the amplicons (figure 2). The insertion and deletion rates
were on average 0.1% and 0.2% per nucleotide, respectively.
Recombinants were not observed in any of these molecular clones.
Sequences were similar to the published sequences of each
molecular HIV-1 clone except for HIV-189.6. Here, our HIV-189.6
strain consists of GAG instead of AGT at positions 2360-2 and of
G instead of A at position 2371 (based on HIV-189.6, GenBank
accession number U39362). The largest genetic distance was
between HIV-1NL4-3 and HIV-189.6 consisting of 13 mismatches,
the lowest genetic distance was 6 mismatches (seen in 4/10
possible pairs of the 5 HIV-1 strains) enabling the investigation of
in vitro recombination (figure 2, orange bars).
In vitro Recombination Frequency is Influenced by RT-
PCR Conditions
PCR conditions can influence the formation of artificial
chimeras [21,22,27]. To test the effect of in vitro recombination
during RT-PCR, a 5-virus-mix was generated consisting of HIV-
1HXB2, HIV-1NL4-3, HIV-1JR-CSF, HIV-189.6, and HIV-1YU2. The
molecular HIV-1 clones were mixed in approximate same
amounts. In each of these and the following experiments, the
exact same volume of the 5-virus-mix, the equivalent of 100,000
HIV-1 RNA copies, was used. After viral RNA was extracted, it
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was reverse transcribed using three different RT enzymes:
Transcriptor High Fidelity RT, M-MuLV RT, RNase H2, and
SuperScript III RT. Each cDNA synthesis was performed in
duplicate. cDNA was amplified by outer and inner PCRs and
pyrosequenced (table 2). A total of 1,649–100,263 reads were
obtained per sample and artificial recombination was estimated
using Recco. We found 30.6–37.1% of all reads to be artificial
recombinants when the cDNA was amplified using standard PCR
conditions and no adjustment of input copy numbers for nested
PCR was performed (table 3, PR1-2).
To reduce the high in vitro recombination frequency, PCR
cycling conditions were optimized by increasing the elongation
time to minimize the occurrence of prematurely terminated
extension events [32], increasing dNTP and oligonucleotide
concentrations, and omitting the final extension step [27]
(table 2). Furthermore, after the first PCR, amplicons were
quantified and 105 DNA copies were transferred to the second
round of amplification. With these modifications, the artificial
recombination rate was reduced to 0.9–2.6% (table 3, PR3-8), as
measured in six independent samples. The choice of the reverse
transcriptase did not influence the artificial recombination rate.
Characteristics of False Haplotypes Induced by in vitro
Recombination
In the haplotypes reconstructed by ShoRAH, we observed the
original strains together with other sequences. The latter can be
subdivided in two classes: 1. recombinants of the strains (in vitro
recombinants) and 2. viral variants harbouring artificial substitu-
tions and/or indels (here called erroneous haplotypes). Applying
standard RT-PCR conditions (samples PR1 and PR2), 53.6 and
43.9% of all reconstructed haplotypes, respectively, were classified
as in vitro recombinants (table 3). These rates were substantially
higher than the estimates of in vitro recombinants by Recco, which
can be explained by the different algorithms and subsequent
procedures used as explained in materials and methods. Figure 3
shows the 23 in vitro recombinants found at frequencies $1% of
the viral population in samples PR1 and PR2, 17 of which could
be found in both samples. Two recombination events per chimera
can be clearly assigned to four in vitro recombinants (m, q, r and t,
figure 3); for the remaining 19 in vitro recombinants, one
recombination event can be clearly identified, although the
occurrence of more than one recombination event cannot be
excluded. For samples PR3-8, where optimized RT-PCR condi-
Figure 1. Substitution and insertion/deletion rates and their sources using 454 pyrosequencing. A) The molecular full-length HIV-1 clone
pYK-JRCSF was used to generate three different samples for the determination of error rates and error sources during the different steps of sample
preparation. The blue (left) pathway indicates the procedure NGS, i.e., no amplification step was performed before emulsion PCR and
pyrosequencing. The green (right) pathway shows the procedure PCR-NGS, i.e., the target was amplified once prior to 454 emulsion PCR/
pyrosequencing. The orange (middle) pathway depicts the commonly used procedure RT-2PCR-NGS to reverse transcribe, amplify and sequence HIV-
1 RNA genomes reflecting the errors that will occur using patients’ plasma samples to analyze HIV-1 haplotypes. Detailed description of each step is
given in the materials and methods section. B) Error rates per positions are shown for forward reads (left) and reverse reads (right). For each duplicate,
one example is shown (always sample a as presented table 1).
doi:10.1371/journal.pone.0074249.g001
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tions were used, including limited input copy number, no in vitro
recombinants were found at frequencies $1%. None of the 472
clones analyzed using single genome amplification was an in vitro
recombinant. These results are consistent with the estimated
recombination rates by Recco (table 3).
Haplotype Reconstruction by ShoRAH Reveals Different
Frequencies of True Haplotypes in Different
Methodological Settings
ShoRAH was applied for haplotype reconstruction from 454
pyrosequencing data obtained from the 5-virus-mix containing
HIV-1HXB2, HIV-1NL4-3, HIV-1JR-CSF, HIV-189.6, and HIV-1YU2.
The true haplotypes were successfully reconstructed in the
following frequencies in these six samples obtained using
optimized amplification conditions (PR3-8, table 3): 4.5–6.8%
HIV-1HXB2, 32.9–45.4% HIV-1NL4-3, 22.9–26.4% HIV-1JR-CSF,
9.6–13.2% HIV-1YU2, and 11.7–19.9% HIV-189.6. Three inde-
pendent single genome amplification experiments, using the same
5-virus-mix, resulted in similar frequencies of 5.8–12.4% HIV-
1HXB2, 36.1–42.1% HIV-1NL4-3, 23.4–32.5% HIV-1JR-CSF, 11.7–
13.0% HIV-1YU2, and 10.3–14.8% HIV-189.6 (table 3).
Haplotype frequency analysis based on 454 pyrosequencing
data obtained using standard amplification conditions showed that
less than 30% of all reads belong to the true haplotypes (PR1 and
PR2, table 3). This leads to a substantial underestimation of the
frequency of each true haplotype as compared to the proportions
obtained by single genome amplification or 454 pyrosequencing
from samples amplified applying optimized conditions (table 3).
Discussion
Characterizing the diversity and evolutionary dynamics of virus
populations within infected hosts is of great importance. For
instance, it provides insights into virus escape mechanisms and
development of drug resistance. Haplotype determination can be
of therapeutic relevance, because pre-existing minority drug-
resistant variants present in a patient can increase the risk of
therapy failure as shown for HIV-1 in a recent meta-analysis [8].
NGS technologies enable the fast acquisition of thousands to
millions of sequences from one sample, making it a powerful tool
to study diverse virus populations. However, the analysis can be
hampered by several experimental errors, occurring both during
library preparation and sequencing (reviewed in [11]). For data
analysis, two major in vitro artifacts have to be considered: 1)
substitution and indel errors and 2) in vitro recombinants. Both can
lead to wrong estimates of diversity within a virus population. This
artificial diversity is difficult to distinguish from the real diversity
especially for HIV-1, as the mutation rate is high and recombi-
nation also occurs frequently in vivo [33].
We designed a control experiment to estimate the substitution
and indel error rates at each different amplification step of 454
pyrosequencing and of the sequencing technology itself. We used
the same HIV-1 full-length plasmid, obtained from a single
bacterial clone, and processed it with different techniques to
estimate the error rate at each step of the pyrosequencing
technology. The indel rates did not differ substantially between the
different steps and occurred predominantly in homopolymeric
regions clearly showing that these errors were generated during
the pyrosequencing step [12,34].
The substitution rate was .10-fold higher as previously
described for non-pre-amplified genomic DNA fragments [12].
This might reflect the substitutions introduced by bacteria during
the numerous duplications of the transfected plasmid. We
expected that the substitution rate is higher in the samples
generated by RT-PCR followed by outer and inner PCRs than in
samples amplified only once prior to NGS. Interestingly, the
substitution rates were only marginally higher in the PCR-NGS
approach. Again, it might be possible that the overall diversity of
plasmids obtained from bacteria after numerous duplications leads
to a substantial amount of plasmids, which will not result in the
generation of intact virus particles in transfected 293T cells. Thus,
the transfection and the harvest of cell-free supernatant would
display a bottleneck resulting in a less heterogeneous virus
population compared to the plasmid ‘‘population’’. In summary,
our RT-2PCR-NGS experimental procedure showed an average
substitution rate of ,0.1%, which is consistent with previous
studies [13,35–39].
In vitro recombination represents a more severe problem
especially for haplotype analysis of amplified viral RNA genomes.
In our set-up, mixing five diverse virus strains, using standard
Table 1. Substitution and insertion/deletion rates per base of different procedures for amplicon generation.
sample* procedure analysis strategy
total
reads
total reads
analyzed
total bases
analyzed
insertion
rate [%]
deletion
rate [%]
substitution
rate [%]
a NGS forward reads 3,898 1,463 421,588 0.19 0.31 0.06
b NGS forward reads 1,649 685 197,238 0.17 0.19 0.08
a PCR-NGS forward reads 50,173 21,214 6,106,238 0.16 0.22 0.14
b PCR-NGS forward reads 100,263 39,758 11,358,035 0.21 0.23 0.16
a RT-2PCR-NGS forward reads 37,724 16,798 4,842,383 0.19 0.20 0.11
b RT-2PCR-NGS forward reads 55,337 28,511 8,217,013 0.17 0.19 0.12
a NGS reverse reads 3,898 2,434 705,284 0.63 0.56 0.14
b NGS reverse reads 1,649 963 279,122 0.66 0.43 0.15
a PCR-NGS reverse reads 50,173 28,697 8,276,817 0.28 0.04 0.11
b PCR-NGS reverse reads 100,263 53,266 15,260,156 0.29 0.05 0.14
a RT-2PCR-NGS reverse reads 37,724 20,915 6,034,401 0.25 0.05 0.11
b RT-2PCR-NGS reverse reads 55,337 26,804 7,744,407 0.40 0.07 0.08
*each sample was done in duplicate, the sample name a and b helps to distinguish the duplicates from each other.
NGS, next-generation sequencing; RT, reverse transcription.
doi:10.1371/journal.pone.0074249.t001
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Figure 2. Substitution rates of each virus strain used to generate the 5-virus-mix. Each of the HIV-1 stocks was pyrosequenced separately
to control for the purity of each virus strain. The y-axis shows the substitution rate per base according to the reference within the analyzed 271 bp
long fragment (amino acids 10–99 of the HIV-1 protease, nt 2279–2549 based on HIV-1HXB2). The x-axis shows the positions on the sequence. The
orange bars indicate differences in the nucleotide sequences of the five virus strains.
doi:10.1371/journal.pone.0074249.g002
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amplification procedures and applying a very strict analysis by
Recco, the in vitro recombination frequency reached up to 37%.
Analysis by ShoRAH and manual inspection revealed an in vitro
recombination frequency of up to 53.6%. These numbers may still
underestimate the real in vitro recombination frequency, since up
to 27.6% of false haplotypes were not clearly classifiable in these
samples. Artificial chimeras inflate viral diversity estimates and, on
the other hand, lead to wrong frequency estimates of the true
haplotypes. Optimizing the amplification conditions and limiting
the input DNA copy numbers in the second, outer PCR reduced
the in vitro recombination rate to 0.9–2.6%. It has been previously
shown that the input DNA copy number is a critical factor in the
generation of artificial recombinants [19]. Despite these optimized
conditions, our in vitro recombination rates were still higher than
previously reported rates of 0.11–0.89% also using optimized PCR
conditions [25,28,33,38]. One major dissimilarity between our
experimental approach and those methods was the template used.
We performed a RT-PCR starting with HIV-1 RNA whereas the
RT step was omitted in the other approaches, i.e., they started
with viral DNA. It is known that prematurely terminated
amplicons during PCR are mainly responsible for in vitro
recombination in PCR reactions [20,22,25–27,36,40,41]. Howev-
er, in RT-PCR procedures, prematurely terminated cDNA
fragments during cDNA synthesis can additionally serve as
primers in subsequent amplifications [29]. Fang et al. showed that
the in vitro recombination rate was approximately 3-fold higher
when RT-PCR was compared to PCR alone (6.49% vs 2.65%,
respectively) [29]. An in vitro recombination rate of 1.56%, i.e.,
more comparable to ours, has been recently published applying
RT-PCR to generate amplicons for subsequent NGS procedures
[42]. In a recent publication, Jabara et al. showed that by using
degenerated primers for cDNA synthesis, PCR artifacts can be
excluded from further analysis [16]. This approach is useful to
exclude polymerase-induced misincorporations and PCR-induced
recombination; however, it cannot identify RT-induced errors and
recombinants.
Table 2. Detailed amplification conditions.
NGS PCR-NGS RT-2PCR-NGS PR1+ PR2 PR3 - PR8
standard RT-PCR
conditions
standard RT-PCR
conditions
optimized RT-PCR
conditions
HIV-1 strains –––––– HIV-1JR-CSF –––––– ––––––––––––– 5-virus-mix
a –––––––––––––
cDNA synthesis
input RNA copies – – ,40,000 ,30,000 ,35,000
RT enzyme – – Transcriptor RT Transcriptor High Fidelity RT Transcriptor High Fidelity RT (PR3+4)
M-MuLV RT, RNase H2 (PR5+6)
SuperScript III RT (PR7+8)
1st (outer) PCR
input cDNA copies – – n.p. n.p.b ,10,000
dNTPs (mM) – – 0.2 0.2 0.4
oligonucleotides (mM each) – – 0.4 0.4 1
FastStart High Fidelity DNA polymerase (U) – – 1.25 1.25 3
denaturation 94uC (sec) – – 15 15 30
annealing 55uC (sec) – – 30 30 60
elongation 72uC (sec) – – 30 30 60
PCR cylces – – 30 30 30
final extention 72uC (min) – – 8 8 none
PCR product purification – – yes yes yes
2nd (inner) PCR
input DNA copies – – n.p.c n.p.c 100,000
dNTPs (mM) – 0.2 0.2 0.2 0.4
oligonucleotieds (mM each) – 0.4 0.4 0.4 1
FastStart High Fidelity DNA polymerase (U) – 1.25 1.25 1.25 3
denaturation 94uC (sec) – 15 15 15 30
annealing 55uC (sec) – 30 30 30 60
elongation 72uC (sec) – 30 30 30 60
final extention 72uC (min) – 8 8 8 none
PCR cylces – 40 40 40 35
All concentrations are given per reaction.
n.p. qPCR was not performed.
a5-virus-mix consists of the HIV-1 strains JR-CSF, NL4-3, HXB2, YU2 and 89.6 (see also Materials and Methods).
b3/23 ml of cDNA was used for the 1st PCR reaction, this corresponds to ,4,200 cDNA copies.
c10/50 ml of purified, undiluted 1st PCR product was transferred to the 2nd PCR.
doi:10.1371/journal.pone.0074249.t002
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It must be noted that our approach to amplify an almost equal
mixture of five divergent virus strains is an extreme example of a
heterogeneous population that enhances the likelihood of detect-
able recombination events. If the population is homogeneous, one
Figure 3. Major in vitro recombinant haplotypes assigned by ShoRAH. Haplotypes were aligned to the five reference strains and
characterized. The top part shows the five virus strains (true haplotypes) of the 5-virus-mix and the bars indicate the specific mutation for each strain
distinguishing it from the other four virus strains. The corresponding nucleotides and positions are indicated. HIV-1HXB2 has one unique mutation at
position 84 (reference numbering 2362) that is indicated in grey. The mutations for HIV-1NL4-3 are marked in blue, in HIV-1JR-CSF in green, in HIV-189.6
in red, and in HIV-1YU2 in orange. Dark colours indicate unique mutations, light colours indicate differences to other strains but not unique for the
respective strain. The bottom part shows all recombinant haplotypes found at 1% and higher frequencies. Triangles indicate positions were a specific
nucleotide is expected according to the corresponding strain, but is missing. The Nucleotide positions in the sequences are indicated.
doi:10.1371/journal.pone.0074249.g003
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will not find artificial chimeras to such an extent, but this does not
mean that in vitro recombination does not occur. Rather, it means
that one cannot identify any recombination event, because such an
event can only be seen when it occurs between two different DNA
molecules that can be distinguished by their genetic dissimilarity.
In fact, a PCR-generated recombinant can only be the third most
frequent haplotype if it is a chimera of the two most abundant ones
[22]. On the other hand, the HIV-1 population of an infected
individual is expected to show the classical quasispecies profile,
with one dominant master sequence and a large number of low-
abundant haplotypes. Thus, in vitro recombination between
different haplotypes will be less evident. Nevertheless, it is
important to know the possible in vitro recombination frequency
within a sample, for example, when investigating superinfections.
The RT step in our experiments did not particularly affect the
recombination rates. One reason could be that rather a short
amplicon (290 bp) was amplified. Amplicon length can influence
recombination rates. Two studies reported a low PCR-induced
recombination rate (below 1%) within a short amplicon (120–
265 bp) [26,28]. Amplification of a longer amplicon (1.5 kb) led to
higher recombination rates [43]. Fang et al. showed that in vitro
recombination rates were higher in RT-PCR than PCR alone
when amplifying a long molecule of over 4 kb [29]. The reasons
might be lower efficiencies of reverse transcriptases to generate
long amplicons, or that RNA is less stable than DNA, i.e.,
degraded RNA can lead to incomplete cDNAs. Amplicon sizes are
increasing as a result of enhanced NGS read lengths; consequent-
ly, RT-PCR artifacts might become more abundant.
In summary, we have developed an optimized RT-PCR
protocol suitable to amplify and sequence HIV-1 RNA genomes
via 454 pyrosequencing exhibiting low error rates. We show that
abundant in vitro recombinants influence haplotype reconstruction
and lead to artificially high diversity as well as to a bias in
quantification of true haplotypes present in the viral population.
Thus, it is crucial to estimate and minimize the in vitro
recombination frequency as well as to consider PCR- and RT-
induced artificial errors in any subsequent analysis in terms of
characteristics and frequencies of variants, especially those of RNA
sources.
Materials and Methods
Viruses
Virus stocks were generated by separate transfection of 293T
cells with each of the following subtype B HIV-1 full-length
plasmids using LipofectamineTM2000 (Invitrogen) according to the
manufacturer’s protocol. The HIV-1 full-length plasmids were
obtained through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH: pYK-JRCSF
from Irvin S.Y. Chen and Yoshio Koyanagi; pNL4-3 from
Malcolm Martin; pYU2 from Beatrice Hahn and George M.
Shaw, p89.6 from Ronald G. Collman, and pHXB2 was kindly
provided by Marek Fischer. 48 h post transfection, virus-contain-
ing supernatant was collected and centrifuged for 5 min at
3,000 rpm and then filtered through 0.22 mm SterilflipH (Milli-
pore) to obtain cell-free virus stocks. For the 5-virus-mix,
approximate same amounts of these molecular clones were mixed
based on HIV-1 RNA copy numbers estimated by quantitative
real-time PCR (qPCR). Viral stocks and mixtures were stored at
280uC.
RNA Isolation, cDNA Synthesis, and Amplification of HIV-
1 Protease Gene
104–107 HIV-1 RNA copies of each HIV-1 stock or 105 HIV-1
RNA copies of the 5-virus-mix were used to isolate viral RNA
using the NucleoSpinH RNA Virus Kit (Macherey and Nagel)
according to the manufacturer’s protocol. HIV-1 RNA was treated
with 5 U DNase (DNase I recombinant, RNase-free; Roche) for
30 min at 25uC followed by inactivation for 15 min at 70uC.
DNase-treated RNA was reverse transcribed using an HIV-1
specific oligonucleotide RT pol 2787 59-GTTCTCTGAAATC-
TAC-39 (2772–2787 nt; this and the following oligonucleotide
positions are based on HIV-1HXB2, GenBank accession number
K03455) and different reverse transcriptases (RT) following the
manufacturers’ protocols: Transcriptor Reverse Transcriptase
(Roche), Transcriptor High Fidelity cDNA Synthesis Kit (Roche),
M-MuLV Reverse Transcriptase, RNase H2 (Finnzymes), or
SuperScript III RT (Invitrogen).
The outer PCR was performed using the FastStart High Fidelity
PCR System (Roche), the forward oligonucleotide gag 2150 59-
AGCCAACAGCCCCACCAG-39 (nt 2150–2167) (RT-2PCR-
NGS and PR1+2, table 2) or gag 2142 59- CAGACCAGAGC-
CAACAGC-39 (nt 2142–2159) (PR3-8, table 2) and the reverse
oligonucleotide pol 2727rc 59-CTGGAGTATTGTATG-
GATTTTCAGG-39 (nt 2703–2727) (RT-2PCR-NGS and
PR1+2, table 2), or pol 2787rc 59-GTTCTCTGAAATCTAC-
TAATTTTCTCC-39 (nt 2761–2787) (PR3-8, table 2). All
oligonucleotides where synthesized by Microsynth. Detailed
amplification protocols are given in table 2. The PCR product
was purified using the NucleoSpinH Extract PCR purification Kit
(Macherey and Nagel) according to the manufacturer’s descrip-
tion. Inner PCR was performed using forward oligonucleotide PR
primer A 59-CGTATCGCCTCCCTCGCGCCA-TCAG-MID-
ATCACTCTTTGGCARCGACC-39 and reverse oligonucleotide
PR primer B 59-CTATGCGCCTTGCCAGCCCGC-TCAG-
MID-CCTGGCTTTAATTTTACTGGTACAG-39 including A
and B sequences at the 59-ends necessary for the 454 FLX/
Titanium pyrosequencing method, respectively, different multi-
plex identifiers (MID) and HIV-1 specific parts (underlined; nt
2259–2279 and nt 2569–2593, respectively). The PCR products
were purified using the NucleoSpinH Extract PCR purification Kit
(Macherey and Nagel) or the Agencourt AMPure XP PCR
purification Kit (Beckman Coulter) according to the manufactur-
ers’ descriptions.
cDNA/DNA Quantification
The cDNA was quantified by qPCR with the oligonucleotides
gag 2142 59-CAGACCAGAGCCAACAGC-39 (nt 2142–2159)
and pol 2787rc 59-GTTCTCTGAAATCTAC-
TAATTTTCTCC-39 (nt 2761–2787). qPCR was performed
using a real-time cycler ABI7500 (Applied Biosystems) as follows:
95uC-39, 506(94uC-1599, 55uC-3099, 72uC-3099) followed by a
melt curve analysis in a total volume of 20 ml containing 5 nM
(ROX, Invitrogen), 1.5 mM MgCl2, 0.4 mM dNTPs, 0.26SYBR
Green (Invitrogen), 0.4 mM of each oligonucleotide and 0.5 U
JumpStart Taq Polymerase (Sigma). A standard was comprised of
a 10-fold dilution series of an equimolar mix of DNA molecules
from each viral strain. The first (outer) PCR amplicons were
quantified similarly except that oligonucleotides pol 2316 59-
GCTCTATTAGATACAGGAGCAG-39 (nt 2316–2337) and pol
2593rc 59-CCTGGCTTTAATTTTACTGGTACAG-39 (nt
2569–2593) were used.
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Preparation of Adaptor Ligated HIV-1 Fragment
A restriction endonuclease digestion was performed with AhdI
and BsrGI (New England Biolabs) using the HIV-1 full-length
plasmid pYK-JRCSF. The 381 bp long fragment (2281–2661 nt)
was purified (QIAquick Gel Extraction Kit, Qiagen). 59-adaptor
(59-GCCTCCCTCGCGCCATCAG-MID-C-39 plus 59-phos-
phat–MID-CTGATGGCGCGAGGGAGGC-39) and 39-adaptor
(59-GCCTTGCCAGCCCGCTCAG-MID-39 plus 59-phosphate-
GTAC-MID-CTGAGCGGGCTGGCAAGGC-39) were ligated
to the fragment using T4 DNA Ligase (New England Biolabs).
Adaptor-ligated fragments were gel purified.
454 Pyrosequencing
DNA was measured using the Quant-iTTM PicoGreenH dsDNA
Assay (Invitrogen) according to the manufacturer’s protocol.
Equimolar DNA amounts were pooled for emulsion PCR.
Pyrosequencing was performed with the GS FLX System using
the GS FLX Titanium MV emPCR Kit (Lib-A) or the GS Junior
System using the GS Junior Titanium emPCR Kit (Lib-A) (Roche-
454 Life Sciences).
Single Genome Amplification
The frequencies of the five virus strains in the 5-virus-mix
sample used for the standard PCR protocol were investigated
using single genome amplification. cDNAs generated with the
three RT enzymes Transcriptor RT, Transcriptor High Fidelity
cDNA Synthesis Kit, M-MuLV RT, RNase H2, was diluted in
such a way that each amplicon was derived from one cDNA copy
(a maximum of 1 of 5 PCR reactions were positive). qPCR was
performed in a real-time cycler ABI7500 (Applied Biosystems) as
follows: 94uC-59, 506(94uC-1599, 55uC-3099, 72uC-4599) followed
by a melt curve analysis in a total volume of 20 ml containing
5 nM (ROX, Invitrogen) 1.5 mM MgCl2, 0.4 mM dNTPs,
0.16SYBR Green (Invitrogen), 0.4 mM of the oligonucleotides
gag 2023 59-GGCTGTTGGAAATGTGGAAAGG-39 (nt 2023–
2044) and pol 2593rc 59-CCTGGCTTTAATTTTACTGGTA-
CAG-39 (nt 2569–2593), and 1 U JumpStart Taq Polymerase
(Sigma). Nucleotide sequence analysis of single genome amplicons
were performed using the BigDyeH Terminator v1.1 Cycle
Sequencing Kit and an ABI3130 sequencer (Applied Biosystems).
Data Analysis
The analyses of error rates for samples NGS, PCR-NGS and
RT-2PCR-NGS were done separately for forward reads and
reverse reads and restricted to the region nt 2281–2569 (based on
HIV-1HXB2) that overlaps in all three experimental set ups.
Substitutions, insertions and deletions were analyzed by aligning
reads to the HIV-1JR-CSF reference sequence after removal of
reads with gaps of .10 nt. The alignments were computed with
needle (implementing the Needleman-Wunsch algorithm), from
the software suite EMBOSS [44] and the differences were counted
as errors. Analysis of PR1-8 was done on the region nt 2279–2549
(based on HIV-1HXB2). Haplotype reconstruction was performed
using the software ShoRAH (Short Read Assembly into Haplo-
types) [45], a tool developed to correct sequencing errors in order
to reconstruct the true local variants present in the virus
population. ShoRAH clusters the reads (it groups them according
to their similarity) and removes the intra-cluster variation to
eliminate sequencing errors. The recombination analysis was
performed using the software Recco [46]. Each read was included
in a multiple sequence alignment with the five reference sequences
(the viral strains in the 5-virus-mix) computed with muscle [47]
and then passed to Recco. This software computes the number of
‘‘savings’’, i.e., number of mismatches saved when explaining the
read by a recombination event between two viral strains and
mutations, rather than by a single strain and mutations only. For
each sample, a histogram was produced counting the number of
reads with a given number of savings. The proportion of
recombinant reads was estimated on each sample by comparing
the results obtained on the real reads to those results of a set of
simulated reads obtained from the viral strains by substitutions
only. In this analysis, reads were defined as recombinant when
Recco assigns a savings value higher than two, which was the
maximum value observed on the simulated reads. It is important
to say that this analysis tends to underestimate the number of
recombinant reads. In fact, even on datasets where all reads are
recombinant, Recco reports saving values of two or less for a
substantial fraction of the reads.
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